LabConnect Expands North American Headquarters in Seattle
The success of LabConnect’s Scientific Operations Support (SciOps) team and overall company growth are behind its move to larger quarters in Seattle’s historic district.
“We needed to expand because we are growing,” said LabConnect President and Chief Executive Officer Eric Hayashi. “But beyond the additional space needed for our core office functions, we wanted to create just-in-time space for our growing SciOps team members who spend most of their time off site with clients. This move will give us room to double our capacity and allow us to better serve our clients.”
LabConnect provides central laboratory testing services to the biopharmaceutical industry through a global network of regional and local laboratories. The SciOps team is a special unit comprised of industry experts with a minimum of 10 years of experience who offer short- or long-term functional outsourcing services for pharmaceutical research.
“Our customers want to focus on getting the job done well, not on the human resources aspects,” Hayashi said. “We help with both. We provide experienced research professionals and take care of all the details such as payroll and benefits. Demand for this service has been strong since the beginning and it is still growing.”
LabConnect’s new headquarters is in Seattle’s historic Mutual Life Building at 605 First Ave., Ste. 300. Contact LabConnect at 206-322-4680 or by email at [email protected].
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
